Düsseldorf (Germany)

duesseldorf

oval blue Kopie Cancer treatment
oval green Kopie Immunotherapy

Roermond (Netherlands)

roermond Produktieweg

oval blue Kopie Cancer treatment
oval green Kopie Immunotherapy

Keihan Clinic Osaka

cus10

oval blue Kopie Cancer treatment
oval green Kopie Immunotherapy

Kobe Clinic Kobe

kobe

oval blue Kopie Cancer treatment

R Mirai Clinic Tokyo

rmirai

oval blue Kopie Cancer treatment

 

Immunotherapy Lab Osaka

Immunotherapy

oval pink Cell Processing Center

 

gcmaf startseite

cancer vaccine startseite

gene therapy startseite

Comparison of 1st and 2nd Generation GcMAF

GcMAF (Gc Protein derived
Macrophage Activating Factor)

For the treatment for cancer, HIV and immune system diseases.
 
treatment head13

 

Comparison of 1st and 2nd Generation GcMAF

 

Concentration of 1st generation and Second Generation GcMAF

First Generation GcMAF vs Saisei Mirai Second Generation GcMAF concentration

 

First Generation GcMAF

Dr Nobuto Yamamoto
Dr Nobuto Yamamoto
  • Developed by Dr Yamamoto in 1991
  • Low concentration (100 ng/0.25 ml, 1 dose)
  • Low stability at room temperature and when refrigerated
  • Gc protein isolated from serum using 25-(OH) Vitamin D3 Affinity Column, making the GcMAF unstable
  • Sterilized using 0.22 micron sterile filtration system
  • Tokushima University conducts experiments with 1st Generation and 2nd Generation GcMAF

Goleic GcMAF, GcMAF with oleic acid, is simply first generation GcMAF with some added components but still having the low concentration of the original first generation GcMAF developed over 20 years ago. Due to limited testing and clinical use, the efficacy of Goleic GcMAF is unknown.

 

Second Generation GcMAF

Dr Hitoshi Hori, University of Tokushima Dr Yoshihiro Uto, University of Tokushima Dr Kentaro Kubo, Saisei Mirai
Dr Hitoshi Hori, University of Tokushima Dr Yoshihiro Uto, University of Tokushima Dr Kentaro Kubo, Saisei Mirai
  • 2nd Generation High Dose GcMAF Developed by the University of Tokushima and Saisei Mirai in 2011
  • New patented production process
  • High concentration (1500 ng/0.5 ml, 1 dose)
  • Very high macrophage activating activity
  • Much higher stability even at room temperature *
  • Demonstrated in vitro to increase the rate of maturation of Dendritic Cells (DCs).
  • Sterilized using 0.22 micron sterile filtration system

* Second Generation GcMAF is best stored refrigerated and will stay fully active for over 1 year. Stability tests indicate that 2nd Generation GcMAF is very temperature stable and retains maximum activity even after 4 weeks at room temperature and 1 week at 40 °C (104 °F).

 

GcMAF timeline

 

1991 Dr Yamamoto developed GcMAF
1992 Dr Yamamoto visited Dr Hori at Tokushima University
GcMAF research started at Tokushima University
1998 Dr Uto joined Dr Hori's GcMAF research team
2002 First research papers published on GcMAF in the journals Biotherapy and Comparative Biochemistry & Physiology
2010 Tokushima University began collaborating with Saisei Mirai to develop Second Generation High Dose GcMAF
2011 Second Generation GcMAF produced in our Cell Processing Center (CPC) for patients. Start of clinical use.
2013 Two research papers published in Anticancer Research by Saisei Mirai & Tokushima University
2013 Over 1000 patients treated with Saisei Mirai GcMAF
2014 New research paper published in Anticancer Research by Saisei Mirai & Tokushima University

 

If you wish to purchase GcMAF therapy or make an enquiry, please contact us with details of your disease, current treatment and the quantities of Gc-MAF you require.